G1 Therapeutics (NASDAQ:GTHX) Announces Earnings Results, Misses Estimates By $0.01 EPS

G1 Therapeutics (NASDAQ:GTHX) posted its quarterly earnings data on Wednesday. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01), Zacks reports. G1 Therapeutics had a negative return on equity of 106.04% and a negative net margin of 58.13%. The company had revenue of $14.48 million for the quarter, compared to analyst estimates of $15.21 million. During the same quarter in the prior year, the company posted ($0.53) earnings per share.

G1 Therapeutics Stock Up 7.5 %

Shares of GTHX traded up $0.31 during midday trading on Thursday, hitting $4.44. The company had a trading volume of 730,958 shares, compared to its average volume of 1,255,023. G1 Therapeutics has a 1 year low of $1.08 and a 1 year high of $5.00. The firm has a market capitalization of $232.26 million, a P/E ratio of -4.59 and a beta of 1.71. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.45 and a current ratio of 3.87. The company’s 50-day simple moving average is $3.85 and its 200-day simple moving average is $3.05.

Wall Street Analyst Weigh In

Several analysts recently commented on GTHX shares. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of G1 Therapeutics in a research report on Thursday. Needham & Company LLC reissued a “buy” rating and set a $12.00 price target on shares of G1 Therapeutics in a research report on Wednesday. Finally, Wedbush restated an “outperform” rating and issued a $5.00 price objective (up previously from $4.00) on shares of G1 Therapeutics in a report on Wednesday, February 28th.

Insider Buying and Selling

In related news, insider Rajesh Malik sold 28,600 shares of G1 Therapeutics stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $4.62, for a total value of $132,132.00. Following the completion of the transaction, the insider now owns 169,938 shares in the company, valued at $785,113.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 8.23% of the company’s stock.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.